for select generic drugs.” Those involved aren’t saying the drugs they are targeting for development yet as they research expensive generics driving up premiums for Blue Cross plans across the country.
“It does have the potential to tackle the ongoing insulin cost issue, which desperately needs to come down in price,” Matthew Gibbs, national pharmacy solutions leader for Aon, the global risk, healthcare consulting and professional services firm said of the Blue Cross-Civica venture. “Despite insulin being available for decades, current market pricing makes insulin difficult to afford for many patients right now.
“The biggest question overall is can this new venture manufacture these products at a reduced market price, thus likely driving down other ‘equivalent generics,’ which could benefit the entire market at some point,” Aon’s Gibbs said.
I'm not sure what you mean by that, but I'm not sure what you mean by 'high insulin prices may be'.